Chemical Component Summary

NamePKC412
SynonymsN-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide
Identifiersn/a
FormulaC35 H30 N4 O4
Molecular Weight570.637
TypeNON-POLYMER
Isomeric SMILESC[C@@]12[C@@H]([C@@H](C[C@@H](O1)n3c4ccccc4c5c3c6n2c7ccccc7c6c8c5C(=O)NC8)N(C)C(=O)c9ccccc9)OC
InChIInChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1
InChIKeyBMGQWWVMWDBQGC-IIFHNQTCSA-N

Chemical Details

Formal Charge0
Atom Count73
Chiral Atom Count4
Bond Count81
Aromatic Bond Count30

Drug Info: DrugBank

DrugBank IDDB06595 
NameMidostaurin
Groups
  • approved
  • investigational
DescriptionMidostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors [A19108]. It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
Synonyms
  • 4'-N-benzoylstaurosporine
  • Midostaurin
Brand NamesRydapt
IndicationInvestigated for use/treatment in adult patients with high-risk acute myeloid leukemia (AML) who are FLT3 mutation-positive, agressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
Categories
  • Alkaloids
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • Carbazoles
  • Cytochrome P-450 CYP1A2 Inducers
ATC-CodeL01EX10
CAS number120685-11-2

Drug Targets

NameTarget SequencePharmacological ActionActions
Protein kinase C alpha typeMADVFPGNDSTASQDVANRFARKGALRQKNVHEVKDHKFIARFFKQPTFC...unknownantagonist,inhibitor
Vascular endothelial growth factor receptor 2MQSKVLLAVALWLCVETRAASVGLPSVSLDLPRLSIQKDILTIKANTTLQ...unknownantagonist,inhibitor
Platelet-derived growth factor receptor alphaMGTSHPAFLVLGCLLTGLSLILCQLSLPSILPNENEKVVQLNSSFSLRCF...unknownantagonist,inhibitor
Platelet-derived growth factor receptor betaMRLPGAMPALALKGELLLLSLLLLLEPQISQGLVVTPPGPELVLNVSSTF...unknownantagonist,inhibitor
Receptor-type tyrosine-protein kinase FLT3MPALARDGGQLPLLVVFSAMIFGTITNQDLPVIKCVLINHKNNDSSVGKS...unknownantagonist,inhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL608533
PubChem 9829523
ChEMBL CHEMBL608533
ChEBI CHEBI:63452
CCDC/CSD GOJHAQ